Sir, India with a population of 1.26 billion has seroprevalence rates ranging from 0.2-1%, 0.4-1.09%, and 1.8-4% for HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV), respectively, in the blood donors population. [1] [2] [3] [4] Majority of the blood banks in India are using ELISA-based serologic screening for transfusion-transmissible viral infections (TTIs). The automated platform for chemiluminescence (ACLS) has been introduced in the recent past, as a newer serological screening tool that offers good precision, reliability, and high throughput. [5] Although ACLS appears to be an effective replacement for ELISA, the paucity of published research works in support of ACLS, makes this a mere assumption only. Performance evaluation and feasibility assessment of ACLS for routine TTI screening were done at our center based on its concordance with that of ELISA and nucleic acid test (NAT).
Routine TTI screening of all the blood units collected from 1 st to 30 th September 2015, was done simultaneously by ELISA (DaVinci, Biomérieux, France) for anti-HIV (4 th generation kits), anti-HCV (3 rd generation kits), and hepatitis B surface antigen (HBsAg) (3 rd generation kits); ACLS (Architect i1000 SR, Abbott, USA) for anti-HIV (4 th generation kits), anti-HCV (3 rd generation kits), and HBsAg (3 rd generation kits); and NAT (Procleix Ultrio, Grifols, Hong Kong) for HIV-RNA, HCV-RNA, and HBV-DNA. All the NAT nonreactive units with discordant serology results were subjected to viral load quantification by real-time polymerase chain reaction (RT-PCR) (Cobas TaqMan, Roche, USA) for confirming the infectious status.
Overall, 2.33% (75 of 3213) units were found to be TTI reactive by ≥1 method. Thirty-four (1.05%) units were found to be concordant reactive by all 3 methods, whereas 41 (1.27%) units were reported to have discordant results. Of these 41 Table 1 ]. Repeat serological tests for these 29 samples gave consistent results with that of earlier tests though neither NAT nor the RT-PCR could detect the infectious viral markers. However, these donors were kept under follow-up category to ascertain their infectious status as seroyields. Taking NAT as gold standard, the relative sensitivity and specificity of ELISA were 80.43% and 99.55%, respectively, and those of ACLS were 76.08% and 99.36%, respectively. The observed discrepancies among the 3 methods used, may be due to the different principles of the serological and molecular techniques or of chance occurrence due to the smaller study population. Our preliminary result with ACLS warrants a further study with a larger donor population for confirmation.
The shorter turn-around time and option for STAT tests give ACLS a definite edge over ELISA, especially during the preprocedural TTI screening for apheresis donors. Therefore, with comparable detection rates and faster turnaround time, ACLS appears as an acceptable alternative for ELISA when used with NAT.
Median channel shift less than the cutoff in flow cytometric crossmatch: Not to be ignored!

Sir,
The presence of donor-specific antibodies in the patient's serum is well known to be a factor in the outcome of a renal transplant recipient. There may be multiple causes of the formation of the antibodies including previous transplant, pregnancy, transfusion, or even infections. [1] Flow cytometric crossmatch (FCXM) is a sensitive, quantitative, and objective, yet cost-effective method for detection of donor-specific antibodies. [2] Although it lacks the specificity that would be offered by a Luminex single antigen bead (SAB) assay, it is a useful screening method. In a country like India where Luminex SAB assay is not yet a standard of care due to its cost implications and the majority of the transplants are with living donors, it is extremely important to identify the clues provided by FCXM results.
The standard FCXM is performed by separating the donor lymphocytes and incubating them with patient serum, along with negative and positive controls. This is followed by incubation with fluorescent-labeled anti-human immunoglobulin (Ig), which is specific for Fc part of IgG and antibodies to identify B-and T-cells. [3] The analysis includes calculating the median channel shift (MCS) of median fluorescence intensity (MFI) of the test serum vis-à-vis negative control. A cutoff is set-up by each laboratory individually which in our laboratory is set by testing number of normal sera and the cutoff point is equal to 3 standard deviation (SD). [4] The normal sera were obtained from AB-positive, nonsensitized males, which were also tested on Luminex to confirm the lack of any human leukocyte antigen (HLA) antibody. Using these sera, the cutoff was calculated to be 50 for T-cells and 80 for B-cells, using the 3SD rule. A test is only reported when positive control works satisfactorily for that particular sample. All quality control measures are taken in keeping with the accreditation guidelines vide ISO 15189:2012 as this test is accredited by the National Accreditation Board for Laboratories. Some laboratories also tend to use the 10% cutoff by considering the fluorescence index (FI), which is the percentage shift in the test serum as compared to the positive control ([test serum MFI − negative control MFI]/[positive control MFI − negative control MFI] × 100). [5] Most of the negative FCXMs results that we get have a shift less than or equal to the negative control while the positive cases are well beyond the cutoff. We use the commercial controls as negative sera, every new lot of which is verified by testing them with Luminex SAB assay. Commercial positive controls are run as quality control measure with every test to prove the validity of the test and also meet the requirement by accreditation authorities. We rarely find cases where there is a shift, which is less than that of the cutoff. These cases are usually the ones that lie in the gray zone and an immunologist may be tempted to call them negative. We hereby report two renal transplant cases which had a shift less than the cutoff for FCXM, and which on further evaluation revealed weak donor-specific HLA antibodies (DSA) as detected by Luminex SAB assay. Both these cases were worked up in the mid of 2015.
The first case was a 49-year-old female for whom daughter was the donor and the FCXM revealed T-cell MCS of 29 and B-cell MCS of 36 as compared to the negative control [ Figure 1 ]. The complement-dependent cytotoxic (CDC) crossmatch was negative while there was panel reactive antibody (PRA) of 7% for class I. On further evaluation using Luminex SAB assay, DSA was identified against HLA-B*08, which was donor-specific. However, its MFI was only 1422 (cutoff 1000). Thus, the MCS for T-and B-cells, although less
